1. Home
  2. DUO vs ELUT Comparison

DUO vs ELUT Comparison

Compare DUO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$0.65

Market Cap

38.5M

Sector

Finance

ML Signal

HOLD

Logo Elutia Inc.

ELUT

Elutia Inc.

N/A

Current Price

$0.97

Market Cap

41.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DUO
ELUT
Founded
2011
2015
Country
China
United States
Employees
N/A
26
Industry
Real Estate
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.5M
41.9M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
DUO
ELUT
Price
$0.65
$0.97
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
117.3K
92.7K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
146.77
EPS
N/A
N/A
Revenue
N/A
$12,293,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$0.50
52 Week High
$5.34
$2.60

Technical Indicators

Market Signals
Indicator
DUO
ELUT
Relative Strength Index (RSI) 22.69 45.11
Support Level N/A $0.86
Resistance Level $1.25 $0.99
Average True Range (ATR) 0.11 0.07
MACD -0.01 -0.00
Stochastic Oscillator 3.33 24.24

Price Performance

Historical Comparison
DUO
ELUT

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China. All revenues of the Group are derived from the PRC.

About ELUT Elutia Inc.

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

Share on Social Networks: